Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism
Open Access
- 1 January 2020
- journal article
- research article
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 8 (1), e000871
- https://doi.org/10.1136/bmjdrc-2019-000871
Abstract
Objective Increased hepatic de novo lipogenesis (DNL) is suggested to be an underlying cause in the development of nonalcoholic fatty liver disease and/or insulin resistance. It is suggested that omega-3 fatty acids (FA) lower hepatic DNL. We investigated the effects of omega-3 FA supplementation on hepatic DNL and FA oxidation using a combination of human in vivo and in vitro studies. Research design and methods Thirty-eight healthy men were randomized to take either an omega-3 supplement (4 g/day eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) as ethyl esters) or placebo (4 g/day olive oil) and fasting measurements were made at baseline and 8 weeks. The metabolic effects of omega-3 FAs on intrahepatocellular triacylglycerol (IHTAG) content, hepatic DNL and FA oxidation were investigated using metabolic substrates labeled with stable-isotope tracers. In vitro studies, using a human liver cell-line was undertaken to gain insight into the intrahepatocellular effects of omega-3 FAs. Results Fasting plasma TAG concentrations significantly decreased in the omega-3 group and remained unchanged in the placebo group. Eight weeks of omega-3 supplementation significantly decreased IHTAG, fasting and postprandial hepatic DNL while significantly increasing dietary FA oxidation and fasting and postprandial plasma glucose concentrations. In vitro studies supported the in vivo findings of omega-3 FAs (EPA+DHA) decreasing intracellular TAG through a shift in cellular metabolism away from FA esterification toward oxidation. Conclusions Omega-3 supplementation had a potent effect on decreasing hepatic DNL and increasing FA oxidation and plasma glucose concentrations. Attenuation of hepatic DNL may be considered advantageous; however, consideration is required as to what the potential excess of nonlipid substrates (eg, glucose) will have on intrahepatic and extrahepatic metabolic pathways.Funding Information
- British Heart Foundation (FS/11/18/28633, FS/15/56/31645)
This publication has 54 references indexed in Scilit:
- De novo lipogenesis in the differentiating human adipocyte can provide all fatty acids necessary for maturationJournal of Lipid Research, 2011
- Fructose impairs glucose-induced hepatic triglyceride synthesisLipids in Health and Disease, 2011
- Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small ApolipoproteinsArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosisJCI Insight, 2009
- Differences in partitioning of meal fatty acids into blood lipid fractions: a comparison of linoleate, oleate, and palmitateAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- The acetate recovery factor to correct tracer-derived dietary fat oxidation in humansAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Selective versus Total Insulin Resistance: A Pathogenic ParadoxCell Metabolism, 2008
- The Contribution of Splanchnic Fat to VLDL Triglyceride Is Greater in Insulin-Resistant Than Insulin-Sensitive Men and WomenDiabetes, 2007
- The Triple Threat to Nascent Apolipoprotein BOnline Journal of Public Health Informatics, 2001
- Equilibration of metabolic CO2 with preformed CO2 and bicarbonateFEBS Letters, 1983